Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOPNET: Cessation of Somatostatin Analogues After PRRT in Neuroendocrine Tumours
NCT06345079Phase 2Recruiting
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Oct 2024
- Primary completion
- Sep 2027
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in neuroendocrine tumors (NETs) (2 arms), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoints: Progression-Free Survival at 20 months and Feasibility of subsequent phase 3 trial at 20 months. Started Oct 2024; status: recruiting.
02
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT06345079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06345079.